Yoo‐Joung Ko

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Sharlene Gill · 3 shared papers, 2016–2026 · strength 0.38
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
   • Paper PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced … DOI 10.1200/jco.2016.68.5776↗
2. Ravi Ramjeesingh · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
3. Mustapha Ali Tehfe · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
4. Petr Kavan · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
5. Christina Kim · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
6. James Thomas Topham · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
7. Derek J. Jonker · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
8. Jennifer Jane Knox · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
9. David F. Schaeffer · 2 shared papers, 2022–2026 · strength 0.33
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
10. Daniel John Renouf · 2 shared papers, 2022–2026 · strength 0.33
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
11. Chris J. O’Callaghan · 2 shared papers, 2022–2026 · strength 0.33
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
12. Kelvin Chan · 3 shared papers, 2014–2020 · strength 0.23
    • Paper Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. DOI 10.1016/j.critrevonc.2019.102817↗
    • Paper Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. DOI 10.1016/j.jval.2016.11.002↗
    • Paper A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. DOI 10.1371/journal.pone.0108749↗
13. Joanna M. Karasinska · 1 shared paper, 2026 · strength 0.22
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
14. Kelly Lien · 2 shared papers, 2014–2017 · strength 0.12
    • Paper Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. DOI 10.1016/j.jval.2016.11.002↗
    • Paper A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. DOI 10.1371/journal.pone.0108749↗
15. Doug Coyle · 2 shared papers, 2014–2017 · strength 0.12
    • Paper Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. DOI 10.1016/j.jval.2016.11.002↗
    • Paper A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. DOI 10.1371/journal.pone.0108749↗
16. Ambica Parmar · 1 shared paper, 2020 · strength 0.11
    • Paper Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. DOI 10.1016/j.critrevonc.2019.102817↗
17. Malcolm J. Moore · 1 shared paper, 2016 · strength 0.05
    • Paper PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced … DOI 10.1200/jco.2016.68.5776↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.